

## Fructose controlled ionophoric activity of a cholate–boronic acid†

James R. D. Brown, Inmaculada C. Pintre and Simon J. Webb\*

Cite this: *Org. Biomol. Chem.*, 2014, **12**, 2576

Received 21st January 2014,  
Accepted 27th February 2014

DOI: 10.1039/c4ob00165f

www.rsc.org/obc

### Introduction

The recognition of polyols, in particular saccharides, by boronic acids is an example of a dynamic covalent chemistry that has provided a wealth of applications in supramolecular chemistry, with recent examples in sensing,<sup>1</sup> drug delivery,<sup>2</sup> separation<sup>3</sup> and hydrogel formation.<sup>4</sup> The interaction of lipophilic or membrane-bound boronic acids with saccharides or glycolipids has risen to particular prominence in recent years,<sup>5,2b</sup> driven in part by the development of 2-(hydroxymethyl)phenylboronic acids able to bind a wider range of sugars at close to physiological conditions.<sup>6</sup> Lipophilic boronic acids have also been known for some time to also transport saccharides, particularly fructose, across supported membranes,<sup>7</sup> bulk organic phases<sup>8</sup> and phospholipid bilayers.<sup>9</sup>

Amphiphilic boronic acids are suggested to transport saccharides by forming complexes that are sufficiently lipophilic to diffuse across the membrane. Two mechanisms have been proposed for boronic acid-mediated diol transport across membranes (Fig. 1), with transport either occurring through trigonal planar boronate esters or tetrahedral boronate anions; the pH of the sending phase and boronic acid  $pK_a$  determines which mechanism is followed.<sup>10</sup> A cation is associated with




Fig. 1 Scheme showing the transport of boronic acid–diol complexes through bilayers either as (a) trigonal planar or (b) tetrahedral boron species. (c) Main 1 : 1 boronate complex formed with fructose.<sup>12</sup>

tetrahedral boronate anions, which can be covalently linked to the boronic acid, an added lipophilic tetraalkylammonium salt, or it can be a counterion symported with the sugar from the sending phase.<sup>7,11</sup> In the latter case a crown ether is often added to form a lipophilic complex able to pass through the apolar membrane phase.<sup>10a</sup> Despite the implication that cation transport is concomitant with saccharide transport, boronic acid mediated  $M^+$  transport across phospholipid bilayers has not been explicitly measured and compared to the rate of concomitant saccharide transport.

The ability of lipophilic boronic acids embedded in phospholipid bilayers to complex sugars suggests new ways of controlling ion flux across phospholipid bilayers, with ion flow across the membrane controlled by the presence of biological catechols<sup>13</sup> or saccharides.<sup>14</sup> Saccharides are ideal for controlling ion transport as these highly polar molecules cannot cross the phospholipid bilayer, they will not discharge a pH gradient

Manchester Institute of Biotechnology (MIB) and School of Chemistry, University of Manchester, 131 Princess St., Manchester M1 7DN, UK.

E-mail: S.Webb@manchester.ac.uk

†Electronic supplementary information (ESI) available: NMR spectra of 3.  $K^+$  transport by 3. U-tube picrate transport data. Effect of fructose on  $Na^+$  transport by 3 or 4. See DOI: 10.1039/c4ob00165f






Fig. 2 Boronic acids and cholic acid.

and unlike lipophilic polyols they will not disrupt bilayer membranes. Although the affinities of sugars for most boronic acids is generally rather weak, some sugars, such as fructose, exhibit binding constants with phenylboronic acids in buffer in the order of  $100 \text{ M}^{-1}$ .

Previously we developed cholate-based ionophores that can be turned on or off by complexation to metal ions or proteins.<sup>15</sup> Adding boronic acid mediated recognition/transport with mono- or bis-cholate scaffolds was expected to provide some interesting ionophores, especially as oligocholates are known to transport metal ions and dyes through bilayers, through either channel or carrier mechanisms.<sup>16,17</sup> The high activity of cholates stems from their facial amphiphilicity, which provides hydrophobic convex surfaces that can be presented to the bilayer and concave hydrophilic surfaces that can interact with alkali metal ions.

Linking cholates with boronic acids was hoped to produce saccharide-switchable ion transport across phospholipid bilayers. Fructose forms boronic acid complexes with a variety of geometries and stoichiometries,<sup>12</sup> including 1 : 2 fructose to boronic acid,<sup>12,18</sup> and we wondered if fructose could assemble boronic acid–cholate conjugates into dimers that might form channels<sup>17</sup> or “hairpin” carriers with a sequestered hydrophilic cavity. The compounds we investigated for cation transport ranged from phenylboronic acid 1 and Wulff-type 2-(*N*-methylaminomethyl)phenylboronic acid 2, to a more amphiphilic Wulff-type boronic acid conjugate 3 that has a single facially amphiphilic cholate tail (Fig. 2).

## Results and discussion

### Synthesis of 3

Boronate-cholate derivative 3 was synthesised in two steps from cholic acid 4. The short triethylene glycol spacer was added between the cholate body and the boronic acid to give flexibility around the complexation site and to project it away from the cholate, which will become embedded in the bilayer.

Cholic acid 4 was first coupled to mono-protected 1-(benzyloxycarbonylamino)-3,6-dioxa-8-amino-octane, the product hydrogenolysed, then reductively aminated with 2-formylphenylboronic acid to give compound 3 in 59% yield from the acid.

### Ion transport assays

To screen the ability of these compounds to transport cations through bilayers we chose the phospholipid vesicle based 8-hydroxypyrenetrisulfonate (HPTS  $\text{pK}_a = 7.3$ ) assay,<sup>19</sup> using an interior pH of 6.5 and an exterior pH of 8.5. The exterior pH was selected to be above the  $\text{pK}_a$  of aminomethylboronic acids ( $\text{pK}_a \sim 6.5$ )<sup>7</sup> and corresponding saccharide complexes ( $\text{pK}_a < 6.5$ ),<sup>20</sup> a strategy designed to favour  $\text{M}^+/\text{OH}^-$  co-transport. EYPC/cholesterol vesicles were used as these bilayers have the right balance between fluidity and impermeability. Fluidity allows assembly in the membrane and diffusion through the membrane, but pure EYPC bilayers gave unsatisfactory levels of background leakage.

The choice of buffer was crucial as boronic acid complexation of diols is strongly pH dependent, with the ideal pH between the  $\text{pK}_a$  of the diol and the boronic acid.<sup>21</sup> Buffer type and concentration can also strongly affect the binding of boronic acids to saccharides, with stronger binding at low buffer concentrations.<sup>22</sup> To obtain precise pH control, the standard procedure for the HPTS assay was modified, with HPTS-loaded vesicles directly added to buffer at pH 8.5 rather than addition of an external aliquot of NaOH (the base pulse). The ionophore was then added after 180 s to initiate transport, which also eliminates the jump in fluorescence observed if the base pulse is applied after ionophore addition.

Initially cholate–boronic acid 3 was assayed for its ability to allow sodium ions to cross a bilayer. Addition of cholate–boronic acid 3 ( $10 \mu\text{M}$ ) to give a membrane loading of 5% mol/mol gave an immediate increase in fluorescence that suggested  $\text{Na}^+/\text{H}^+$  antiport or  $\text{Na}^+/\text{OH}^-$  symport across the bilayer of these EYPC/chol vesicles. Cholic acid 4 ( $\text{pK}_a \sim 4.6$ )<sup>23</sup> did not conduct sodium ions across the membrane and gave little transport above the background methanol control (Fig. 3).




Fig. 3 Transport of  $\text{Na}^+$  across EYPC/chol bilayers by boronic acid 2 (●), boronate-cholate 3 (●) and cholate 4 (●). The methanol control has been subtracted from the data. First order curve fits are to guide the eye.



This journal is © The Royal Society of Chemistry 2014

*Org. Biomol. Chem.*, 2014, **12**, 2576–2583 | 2579



complexation to fructose shuts down ionophoric activity due to the lower lipophilicity of the  $\text{Na}^+$ /saccharide/boronate complexes inhibiting partitioning into the bilayer.

The studies presented here may open a pathway towards saccharide-sensitive ionophores, provided that high selectivity for targeted saccharides under physiological conditions<sup>6</sup> can be engineered into the boronic acid moiety. Several design rules can be elucidated for the construction of such saccharide sensitive boronic acid ionophores. The boronic acid must be designed so that the  $\text{pK}_a$  lies below the pH of the sending (exterior) solution. It may not be necessary to have a crown ether or other  $\text{Na}^+$  complexing site appended to the boronic acid for sodium ion transport,<sup>11</sup> as the hydroxyl-lined cholate on **3** did not provide greater activity than simple boronic acid **2**. Other simple saccharides should produce a different effect on ionophoric activity, depending upon binding constant and complex lipophilicity. Covalently linking together cholates into bis(cholate) dimers<sup>17</sup> with boronic acids at both termini did not give any improvement in  $\text{Na}^+$  transport activity, and these compounds also followed a carrier mechanism with similar activity.<sup>31</sup> Transport of other cation/anion combinations are yet to be investigated, although preliminary studies indicate  $\text{K}^+$  is transported in much the same way as  $\text{Na}^+$  (ESI Fig. S6†).

Given recently reported biological applications of a new generation of boronates able to complex to polysaccharides under physiological conditions,<sup>2b,5e,32</sup> work is ongoing to generate new types of boronic acid-based antibiotics that are responsive to the concentration of targeted polysaccharides in the surrounding environment.

## Experimental section

Benzeneboronic acid **1** and cholic acid **4** were purchased from Sigma-Aldrich and used as received. Phospholipids were obtained from Avanti Polar Lipids. Unless otherwise stated, all other reagents and solvents were obtained from commercial suppliers (Sigma-Aldrich, Fluka, Acros and Alfa Aesar). Anhydrous dichloromethane was obtained by distillation from calcium hydride, and anhydrous tetrahydrofuran was obtained by distillation from sodium. Thin layer chromatography (TLC) was carried out using Merck aluminum-backed F254 silica gel plates and visualised with either UV light (256 nm or 365 nm), alkaline aqueous  $\text{KMnO}_4$ , ninhydrin, 2,4-dinitrophenylhydrazine, or cerium molybdate. Preparative column (flash) chromatography was carried out using commercially available normal-phase silica gel. 1-(Benzyloxy carbonylamino)-3,6-dioxo-8-aminooctane and 2-(methylamino-methyl)phenylboronic acid **2** were synthesised according to literature procedures.<sup>33,34</sup>

NMR spectra were measured on Bruker DPX300, AV400, or AMX500 instruments and were assigned using COSY, HMBC, HMQC and DEPT spectra where appropriate. Coupling constants  $J$  are given in hertz (Hz); multiplicities are given as singlet (s), doublet (d), triplet (t), quartet (q), quintet (qn), sextet (sxt), septet (spt), or multiplet (m); broad signals are

indicated by (br). Due to quadrupolar relaxation, the aryl carbon atoms attached directly to boron are not always observed by  $^{13}\text{C}$  NMR.<sup>24</sup> Electrospray mass spectra were measured on Micromass Prospec and Micromass Platform spectrometers; samples were prepared using 50 : 50 : 0.1 acetonitrile–water–formic acid solution. High resolution mass spectra (HRMS) were made on a Thermo Finnegan MAT95 XP instrument. Infrared spectra were recorded on a Bruker Alpha-P spectrometer and analysed using OPUS 6.5 software package. Elemental analysis was performed using a Thermo Scientific FLASH 2000 Series CHNS/O Analyzer. UV-Visible absorption measurements used Sigma Spectrophotometer Silica (Quartz) cuvettes (10 mm pathlength) and were recorded on a Jasco V660 spectrophotometer with Jasco EHC-716 Peltier temperature control. Fluorescence spectroscopy was carried out on a Perkin-Elmer LS55 fluorimeter, with an attached Julabo F25-HE water circulator for temperature control. All pH measurements were recorded on a HANNA pH 112 microprocessor pH meter using a Hamilton MINITRODE pH electrode that was calibrated using Fisher Chemicals standard buffer solutions (pH 4.0 – phthalate, 7.0 – phosphate, and 10.0 – borate). Unless otherwise stated all binding constants and  $\text{pK}_a$  values were determined at 20 °C.

### Synthesis of compound **3**

**N-[8'-(Benzyloxycarbonylamino)-3',6'-dioxaminooctyl]-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholan-24-amide.** To a solution of cholic acid (1 g, 2.4 mmol) in dry dimethylformamide (20 mL) was added *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HBTU, 0.91 g, 2.4 mmol, 1 eq.) and *N,N*-diisopropylethylamine (DIPEA, 0.42 mL, 2.4 mmol, 1 eq.). The reaction mixture was stirred for 1 hour, over which time the solution took on a yellow coloration, indicating the formation of the active benzotriazolyl ester. A solution of 1-(benzyloxycarbonylamino)-3,6-dioxo-8-aminooctane (0.68 g, 2.4 mmol, 1 eq.) in dry dimethylformamide (5 mL) was then added to the solution, which was stirred overnight. The solution was diluted with dichloromethane (50 mL) and washed successively with dilute hydrochloric acid (1 M, 25 mL), saturated sodium hydrogen carbonate solution (25 mL) and brine (25 mL). The organic layer was dried over magnesium sulphate, filtered, and the filtrate evaporated *in vacuo*. Flash chromatography ( $\text{SiO}_2$ , eluent: ethyl acetate–methanol 9 : 1 v/v) of the residue provided the title compound as a white foam (1.06 g, 66%).  $^1\text{H}$ -NMR (400 MHz,  $\text{CD}_3\text{OD}$ , 25 °C):  $\delta_{\text{H}}$  ppm 0.58 (3H, s,  $\text{C}^{18/19}\text{CH}_3$ ), 0.79 (3H, s,  $\text{C}^{18/19}\text{CH}_3$ ), 0.91 (3H, d,  $J = 4.7$  Hz,  $\text{C}^{21}\text{H}_3$ ), 1.15–2.22 (24H, steroid  $\text{CH}/\text{CH}_2$ ), 3.33 (5H, t,  $J = 5.1$  Hz,  $2 \times \text{NCH}_2 + \text{C}^3\text{H}$ ), 3.43–3.53 (8H, m,  $\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_2$ ), 3.73 (1H, m,  $\text{C}^7\text{H}$ ), 3.86 (4H, m,  $\text{C}^{12}\text{H} + \text{OH}$ ), 5.02 (2H, s,  $\text{PhCH}_2$ ), 5.68 (1H, br t,  $J = 5.2$  Hz, amide NH), 6.65 (1H, br, carbamate NH), 7.27 (5H, m,  $\text{CH}_{\text{Ar}}$ ).  $^{13}\text{C}$ -NMR (100 MHz,  $\text{CD}_3\text{OD}$ , 25 °C):  $\delta_{\text{C}}$  ppm 12.5, 17.4, 22.5, 23.3, 26.3, 27.6, 28.1, 30.4, 31.7, 33.1, 34.7, 34.8, 35.4, 35.5, 39.2, 39.4, 39.5, 40.8, 41.6, 46.4, 46.5, 66.7, 68.4, 69.9, 70.0, 70.1, 70.2, 71.8, 73.1, 128.1, 128.2, 128.5, 136.6, 156.7, 174.5. MS (ES+):  $m/z$  673.5  $[\text{M} + \text{H}]^+$ , 695.6  $[\text{M} + \text{Na}]^+$ , 1346.3  $[2\text{M} + \text{H}]^+$ .



**(8'-Amino-3',6'-dioxaminooctyl)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholan-24-amide.** To a solution of *N*-[8'-(benzyloxycarbonyl-amino)-3',6'-dioxaminooctyl]-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholan-24-amide (0.2 g, 0.3 mmol) in methanol (10 mL) was added acetic acid (1.7  $\mu$ L, 0.03 mmol) and 10% palladium on activated charcoal (0.02 g). The reaction vessel was degassed three times and stirred under hydrogen overnight. The solution was filtered over Celite and evaporated *in vacuo* before the addition of dichloromethane (10 mL); the organic layer was washed successively with saturated sodium hydrogen carbonate solution (25 mL) and brine (25 mL). The organic layer was dried over magnesium sulphate, filtered, and the filtrate evaporated *in vacuo* to yield the title compound as a pale yellow oil (0.16 g, 99%). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD, 25 °C):  $\delta_{\text{H}}$  ppm 0.71 (3H, s, C<sup>18/19</sup>CH<sub>3</sub>), 0.92 (3H, s, C<sup>18/19</sup>CH<sub>3</sub>), 1.03 (3H, d, *J* = 6.5 Hz, C<sup>21</sup>H<sub>3</sub>), 1.28–2.34 (24H, steroid CH/CH<sub>2</sub>), 3.15 (2H, t, *J* = 5.3 Hz, CH<sub>2</sub>NH<sub>2</sub>), 3.38 (2H, t, *J* = 4.7, NHCH<sub>2</sub>) 3.58 (2H, t, *J* = 5.9, NHCH<sub>2</sub>CH<sub>2</sub>), 3.69 (4H, s, OCH<sub>2</sub>CH<sub>2</sub>O), 3.73 (2H, t, *J* = 5.1 Hz, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 3.82 (1H, m, C<sup>7</sup>H), 3.97 (1H, m, C<sup>12</sup>H). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD, 25 °C):  $\delta_{\text{C}}$  ppm 13.1, 17.9, 23.3, 24.4, 28.0, 28.8, 29.7, 31.0, 31.3, 33.4, 34.2, 36.0, 36.6, 37.1, 40.3, 40.6, 40.8, 41.1, 43.2, 43.3, 47.6, 48.1, 68.0, 69.2, 70.8, 71.4, 71.5, 73.0, 74.2, 177.2. MS (ES<sup>+</sup>): *m/z* 539.5 [M + H]<sup>+</sup>. HRMS for C<sub>30</sub>H<sub>54</sub>N<sub>2</sub>O<sub>6</sub>: expected 539.4015, found 539.4017.

**(8'-((2-Boronobenzyl)amino)-3',6'-dioxaminooctyl)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholan-24-amide (3).** To a solution of (8'-amino-3',6'-dioxaminooctyl)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholan-24-amide (0.1 g, 0.19 mmol) in anhydrous methanol (5 mL) was added 2-formylphenylboronic acid (28 mg, 0.19 mmol) and stirred for 45 minutes. The reaction mixture was cooled to 0 °C and sodium borohydride (36 mg, 0.95 mmol) was added slowly portionwise, the resulting solution was stirred for 45 minutes at 0 °C and for a further 3 hours at room temperature. The solution was diluted with dichloromethane (20 mL) and washed successively with dilute HCl (1 M, 5 mL), saturated sodium hydrogen carbonate solution (5 mL) and brine (5 mL). The organic layer was dried over magnesium sulphate, filtered and the filtrate evaporated *in vacuo* to yield the title compound **3** as a white foam (116 mg, 91%). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD, 25 °C):  $\delta_{\text{H}}$  ppm 0.70 (3H, s, C<sup>18/19</sup>CH<sub>3</sub>), 0.92 (3H, s, C<sup>18/19</sup>CH<sub>3</sub>), 1.01 (3H, d, *J* = 6.7 Hz, C<sup>21</sup>H<sub>3</sub>), 1.05–2.35 (24 H steroid CH/CH<sub>2</sub>), 3.09 (2H, t, *J* = 5.7 Hz, CH<sub>2</sub>NH), 3.29 (2H, t, *J* = 5.7 Hz, NH<sub>amide</sub>CH<sub>2</sub>), 3.36 (1H, m, C<sup>3</sup>H), 3.53 (2H, t, *J* = 5.1 Hz, NH<sub>amide</sub>CH<sub>2</sub>CH<sub>2</sub>), 3.67 (4H, m, OCH<sub>2</sub>CH<sub>2</sub>O), 3.81 (3H, t, *J* = 5.4 Hz, CH<sub>2</sub>CH<sub>2</sub>NH + C<sup>7</sup>H), 3.95 (1H, m, C<sup>12</sup>H), 4.07 (2H, s, PhCH<sub>2</sub>), 7.12–7.24 (3H, m, CH<sub>Ar</sub>), 7.39–7.45 (1H, m, CH<sub>Ar</sub>). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD, 25 °C):  $\delta_{\text{C}}$  ppm 13.1, 17.8, 23.2, 24.3, 27.9, 28.8, 29.6, 31.2, 33.3, 34.1, 35.9, 36.5, 37.0, 40.2, 40.5, 41.0, 43.0, 43.2, 48.1, 48.2, 49.1, 49.3, 54.9, 68.0, 69.0, 70.7, 71.2, 71.4, 72.9, 74.0, 79.5, 126.8, 127.7, 128.4, 128.9, 129.2, 131.5, 176.9. MS (ES<sup>+</sup>): *m/z* 637.5 (100%) [M – 2H<sub>2</sub>O + H]<sup>+</sup>, 673.6 [M + H]<sup>+</sup>. HRMS for C<sub>37</sub>H<sub>57</sub>BN<sub>2</sub>O<sub>6</sub>: expected 637.4388, found 637.4372. Elemental analysis for C<sub>37</sub>H<sub>62</sub>BN<sub>2</sub>O<sub>9</sub>·CH<sub>2</sub>Cl<sub>2</sub>: expected C: 58.92%, H: 8.33%, N: 3.62%; found C: 58.46%, H: 8.19%, N: 3.41%.  $\nu_{\text{max}}$ /cm<sup>–1</sup> 3357 (OH), 2930, 2869, 1649, 1214, 1076, 745.

## Procedure for HPTS fluorescent assay of metal ion transport for boronocholates with and without fructose present

A lipid thin film was first prepared by the addition of spectroscopic grade chloroform to egg yolk phosphatidylcholine (EYPC, 40 mg, 52  $\mu$ mol) and cholesterol (5 mg, 13  $\mu$ mol) in a round bottomed flask (5 mL). Chloroform was slowly evaporated *in vacuo* at room temperature to leave a lipid thin film on the interior of the flask. HPTS phosphate buffer (1.2 mL, 100  $\mu$ M HPTS, 20 mM M<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM MCl, pH 6.5 where M<sup>+</sup> = Na<sup>+</sup> or K<sup>+</sup> as appropriate) was added, followed by detachment of the lipid film from the interior of the flask by vortex agitation, and extruded through a polycarbonate membrane (200 nm pore size, 19 $\times$ ). To remove unencapsulated HPTS, an aliquot of the suspension (1 mL) was diluted with phosphate buffer (1.5 mL, pH 6.5) and purified by gel permeation chromatography (GPC) on a PD10 desalting column (eluted with 3.5 mL phosphate buffer). This provided a purified suspension of HPTS-encapsulated vesicles (15.5 mM total lipid concentration).

An aliquot (25  $\mu$ L) of the vesicle suspension was transferred to a fluorescence cuvette containing phosphate buffer (1.975 mL, 20 mM M<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM MCl, pH 8.5 where M<sup>+</sup> = Na<sup>+</sup> or K<sup>+</sup> as appropriate) with stirring (0.19 mM total lipid concentration) and fluorescence measurements were immediately started (ex. 405 nm and 460 nm, em. 510 nm, time interval 8 s) as a function of time. After 180 s the relevant ionophore was added (20  $\mu$ L, 0.01 mM total ionophore concentration, 5 mol%) and vesicles were lysed after 1200 s by the addition of Triton X-100 (25  $\mu$ L, 25% v/v in distilled water). The change in the normalized ratio  $I_{460}/I_{405}$  as a function of time gave the rate of M<sup>+</sup>/OH<sup>–</sup> antiport across the phospholipid bilayer. The above procedure was repeated at fructose concentrations of 0.25 mM, 0.5 mM, 10 mM, 0.1 M, 0.5 M, achieved by ensuring each buffer composition contained the relevant concentration of fructose.

## U-tube metal picrate transport experiments

A chloroform solution of the potentially transporting species (1 mM, 5 mL) was transferred to a glass U-tube (internal diameter 10 mm) and incubated at 25 °C. To one side of the U-tube was added a receiving phase of phosphate buffer (2.5 mL, 20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 6.5), and to the other side was added a source phase of 0.01% sodium picrate in phosphate buffer (2.5 mL, 20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 8.5). Addition of the source phase marked the start of the experiment; aliquots (1 mL) were taken at intervals from the receiving phase and analysed for the presence of picrate by UV spectroscopy (356 nm); after each measurement the sample was immediately replaced back in the receiving phase of the U-tube. The chloroform was stirred (300 rpm) for the entire experiment to aid diffusion through to the receiving phase.

## U-tube fructose transport experiments

A chloroform solution of the potentially transporting species (1 mM, 5 mL) was transferred to a glass U-tube (internal



diameter 10 mm) incubated at 25 °C. To one side of the U-tube was added a receiving phase of phosphate buffer (2.5 mL D<sub>2</sub>O containing 0.75% % 3-(trimethylsilyl)propionic-2,2,3,3-d<sub>4</sub> acid as an internal standard, 20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 6.5), and to the other side was added a source phase of fructose (1 M) and 0.01% sodium picrate in phosphate buffer (2.5 mL D<sub>2</sub>O containing 0.75% 3-(trimethylsilyl)propionic-2,2,3,3-d<sub>4</sub> acid as an internal standard, 20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 8.5). Addition of the source phase marked the start of the experiment; aliquots (0.8 mL) were taken at intervals from the receiving phase and analysed for the presence of D-fructose by <sup>1</sup>H NMR spectroscopy, after each measurement the sample was immediately replaced back to the receiving phase of the U-tube. The chloroform was stirred (300 rpm) for the entire experiment to aid diffusion through to the receiving phase.

### Distribution coefficient determinations

Solutions of relevant ionophores were prepared in 1-octanol (10 mM, 0.5 mL) and sodium phosphate buffer (20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 8.5) was added (0.5 mL). The aqueous-organic mixture was vigorously mixed using a vortex mixer for 180 s before standing for 1 h to allow separation of the organic and aqueous layers. Aliquots (100 µL) of the 1-octanol layer were transferred to a UV-visible cuvette containing HPLC-grade methanol (1.9 mL) and mixed before measurement (260 nm). The procedure was repeated for different fructose concentrations in sodium phosphate buffer (20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 8.5, [fructose] = 0.01, 0.1, 0.5 mol L<sup>-1</sup>). To provide a maximum absorbance reading solutions of relevant ionophores were prepared in 1-octanol (5 mM, 100 µL) and transferred to a UV-visible cuvette containing HPLC-grade methanol (1.9 mL, 0.25 mM total ionophore concentration) and mixed before measurement (260 nm).

### Binding constant estimation with (2-methylamino methylphenyl)boronic acid 2

Following the protocol of Wang *et al.*,<sup>22</sup> a three-component competitive assay with pyrocatechol violet<sup>28</sup> was used to determine the binding constant between 2 and fructose. Two experiments were conducted to determine the equilibrium constants of the competitive system. First, the association for 2 with pyrocatechol violet (PV) was determined ( $K_{eq1}$ ). A solution of PV (2.74 mM, 2 mL) in phosphate buffer (20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 8.5) was transferred to a UV-visible cuvette and a solution of 2 in PV-phosphate buffer (2.74 mM PV, 20 mM Na<sub>n</sub>H<sub>m</sub>PO<sub>4</sub>, 100 mM NaCl, pH 8.5) was titrated into the cuvette. A plot of changes in absorbance (596 nm) as a function of the concentration of 2, and subsequent iterative non-linear curve fitting (Dynafit<sup>35</sup>) of the data provided the binding constant for the PV-2 complex ( $K_{eq1}$ ).

The binding constant for the 2-fructose complex ( $K_{eq2}$ ) was found by titrating a PV-2 solution with fructose. The binding

constant  $K_{eq2}$  was determined by plotting  $1/P$  as a function of  $Q$ , where  $P$  is defined as:

$$P = [L_o] - \frac{1}{QK_{eq1}} - \frac{[I_o]}{Q + 1} \quad (3)$$

where  $L_o$  is the total amount of boronic acid,  $I_o$  is the total amount of PV,  $K_{eq1}$  is the binding constant of the PV-2 complex, and  $Q$  is the ratio of the concentration of free PV to complexed PV,

$$A = \frac{[I]}{[IL]} \quad (4)$$

where  $I$  is the concentration of free PV in solution, and  $IL$  is the concentration of complexed PV in solution. The binding constant for 2 with a diol can be calculated by dividing  $K_{eq1}$  by the gradient of a plot of  $1/P$  vs.  $Q$ .

## Acknowledgements

J.R.D.B. and S.J.W. thank the EPSRC for funding (EP/F055315/1). I.C.P. would like to thank the EU Seventh Framework Programme for a Marie Curie Intra-European Fellowship (Grant PIEF-GA-2012-328025 MagNanoVes).

## References

- (a) R. Nishiyabu, Y. Kubo, T. D. James and J. S. Fossey, *Chem. Commun.*, 2011, **47**, 1106–1123; (b) S. D. Bull, M. G. Davidson, J. M. H. Van Den Elsen, J. S. Fossey, A. T. A. Jenkins, Y.-B. Jiang, Y. Kubo, F. Marken, K. Sakurai, J. Zhao and T. D. James, *Acc. Chem. Res.*, 2013, **46**, 312–326; (c) R. A. Brown, V. Diemer, S. J. Webb and J. Clayden, *Nat. Chem.*, 2013, **5**, 853–860.
- (a) H. Kim, Y. J. Kang, S. Kang and K. T. Kim, *J. Am. Chem. Soc.*, 2012, **134**, 4030–4033; (b) G. A. Ellis, M. J. Palte and R. T. Raines, *J. Am. Chem. Soc.*, 2012, **134**, 3631–3634; (c) Y. Li, W. Xiao, K. Xiao, L. Berti, J. Luo, H. P. Tseng, G. Fung and K. S. Lam, *Angew. Chem., Int. Ed.*, 2012, **51**, 2864–2869.
- (a) C. Lu, H. Li, H. Wang and Z. Liu, *Anal. Chem.*, 2013, **85**, 2361–2369; (b) Y. Liu, L. Ren and Z. Liu, *Chem. Commun.*, 2011, **47**, 5067–5069.
- (a) L. He, D. E. Fullenkamp, J. G. Rivera and P. B. Messersmith, *Chem. Commun.*, 2011, **47**, 7497–7499; (b) Y. Kotsuchibashi, R. V. C. Agustin, J.-Y. Lu, D. G. Hall and R. Narain, *ACS Macro Lett.*, 2013, **2**, 260–264.
- (a) O. Savsunenko, H. Matondo, S. Franceschi-Messant, E. Perez, A. F. Popov, I. Rico-Lattes, A. Lattes and Y. Karpichev, *Langmuir*, 2013, **29**, 3207–3213; (b) A. Kashiwada, M. Tsuboi, N. Takamura, E. Brandenburg, K. Matsuda and B. Kocsch, *Chem.-Eur. J.*, 2011, **17**, 6179–6186; (c) A. Kashiwada, M. Tsuboi, T. Mizuno, T. Nagasaki and K. Matsuda, *Soft Matter*, 2009, **5**, 4719–4725; (d) E. Han, L. Ding and H. Ju, *Anal. Chem.*,





- 2011, **83**, 7006–7012; (e) A. Mahalingam, A. R. Geonnotti, J. Balzarini and P. F. Kiser, *Mol. Pharm.*, 2011, **8**, 2465–2475.
- 6 (a) M. Berube, M. Dowlut and D. G. Hall, *J. Org. Chem.*, 2008, **73**, 6471–6479; (b) M. Dowlut and D. G. Hall, *J. Am. Chem. Soc.*, 2006, **128**, 4226–4227.
- 7 P. J. Duggan, T. A. Houston, M. J. Kiefel, S. M. Levonis, B. D. Smith and M. L. Szydzik, *Tetrahedron*, 2008, **64**, 7122–7126.
- 8 (a) T. Shinbo, K. Nishimura, T. Yamaguchi and M. Sugiura, *J. Chem. Soc., Chem. Commun.*, 1986, 349–351; (b) M.-F. Paugam, L. S. Valencia, B. Boggess and B. D. Smith, *J. Am. Chem. Soc.*, 1994, **116**, 11203–11204; (c) L. K. Mohler and A. W. Czarnik, *J. Am. Chem. Soc.*, 1993, **115**, 7037–7038.
- 9 (a) P. R. Westmark and B. D. Smith, *J. Pharm. Sci.*, 1996, **85**, 266–269; (b) P. R. Westmark, S. J. Gardiner and B. D. Smith, *J. Am. Chem. Soc.*, 1996, **118**, 11093–11100.
- 10 (a) M.-F. Paugam, G. T. Morin and B. D. Smith, *Tetrahedron Lett.*, 1993, **34**, 7841–7844; (b) G. T. Morin, M. P. Hughes, M.-F. Paugam and B. D. Smith, *J. Am. Chem. Soc.*, 1994, **116**, 8895–8901; (c) G. T. Morin, M.-F. Paugam, M. P. Hughes and B. D. Smith, *J. Org. Chem.*, 1994, **59**, 2724–2128.
- 11 J. T. Bien, M. Shang and B. D. Smith, *J. Org. Chem.*, 1995, **60**, 2147–2152.
- 12 J. C. Norrild and H. Eggert, *J. Chem. Soc., Perkin Trans. 2*, 1996, 2583–2588.
- 13 S. Hagihara, H. Tanaka and S. Matile, *J. Am. Chem. Soc.*, 2008, **130**, 5656–5657.
- 14 S. Litvinchuk, N. Sordé and S. Matile, *J. Am. Chem. Soc.*, 2005, **127**, 9316–9317.
- 15 (a) C. P. Wilson and S. J. Webb, *Chem. Commun.*, 2008, 4007–4009; (b) C. P. Wilson, C. Boglio, L. Ma, S. L. Cockroft and S. J. Webb, *Chem.-Eur. J.*, 2011, **17**, 3465–3473.
- 16 (a) P. Bandyopadhyay, V. Janout, L. Zhang, J. A. Sawko and S. L. Regen, *J. Am. Chem. Soc.*, 2000, **122**, 12888–12889; (b) P. Bandyopadhyay, V. Janout, L. Zhang and S. L. Regen, *J. Am. Chem. Soc.*, 2001, **123**, 7691–7696; (c) M. Mehiri, W.-H. Chen, V. Janout and S. L. Regen, *J. Am. Chem. Soc.*, 2009, **131**, 1338–1339; (d) L. Ma, M. Melegari, M. Colombini and J. T. Davis, *J. Am. Chem. Soc.*, 2008, **130**, 2938–2939; (e) Y. Zhao, H. Cho, L. Widanapathirana and S. Zhang, *Acc. Chem. Res.*, 2013, **46**, 2763–2772.
- 17 M. Yoshii, M. Yamamura, A. Satake and Y. Kobuke, *Org. Biomol. Chem.*, 2004, **2**, 2619–2623.
- 18 S. J. Gardiner, B. D. Smith, P. J. Duggan, M. J. Karpa and G. J. Griffin, *Tetrahedron*, 1999, **55**, 2857–2864.
- 19 S. Matile, N. Sakai and A. Hennig, *Transport Experiments in Membranes published in Supramolecular Chemistry: From Molecules to Nanomaterials*, John Wiley & Sons, Ltd., 2012.
- 20 J. Yan, H. Fang and B. Wang, *Med. Res. Rev.*, 2005, **25**, 490–520.
- 21 (a) J. Yan, G. Springsteen, S. Deeter and B. Wang, *Tetrahedron*, 2004, **60**, 11205–11209; (b) M. Vanduin, J. A. Peters, A. P. G. Kieboom and H. Vanbekkum, *Tetrahedron*, 1984, **40**, 2901–2911; (c) P. A. Sienkiewicz and D. C. Roberts, *J. Inorg. Nucl. Chem.*, 1980, **42**, 1559–1575.
- 22 G. Springsteen and B. H. Wang, *Tetrahedron*, 2002, **58**, 5291–5300.
- 23 D. J. Cabral, J. A. Hamilton and D. M. Small, *J. Lipid Res.*, 1986, **27**, 334–343.
- 24 C. J. Ward, P. Patel and T. D. James, *J. Chem. Soc., Perkin Trans. 1*, 2002, 462–470.
- 25 A. Adamczyk-Woźniak, K. M. Borys, I. D. Madura, A. Pawelko, E. Tomecka and K. Żukowski, *New J. Chem.*, 2013, **37**, 188–194.
- 26 Both compounds exhibited a significant lag period due to slow diffusion though the chloroform phase under our experimental conditions. See A. Giannetto, S. Lanza, F. Puntoriero, M. Cordaro and S. Campagna, *Chem. Commun.*, 2013, **49**, 7611–7613.
- 27 M. J. Karpa, P. J. Duggan, G. J. Griffin and S. J. Freudigmann, *Tetrahedron*, 1997, **53**, 3669–3678.
- 28 Z. Zhong and E. V. Anslyn, *J. Am. Chem. Soc.*, 2002, **124**, 9014–9015.
- 29 (a) V. Gorteau, G. Bollot, J. Mareda and S. Matile, *Org. Biomol. Chem.*, 2007, **5**, 3000–3012; (b) B. D. Smith, J. P. Davis, S. P. Draffin and P. J. Duggan, *Supramol. Chem.*, 2004, **16**, 87–90.
- 30 J.-P. Behr, M. Kirch and J.-M. Lehn, *J. Am. Chem. Soc.*, 1985, **107**, 241–246.
- 31 J. R. D. Brown, PhD thesis, University of Manchester, 2013.
- 32 T. A. Houston, *ChemBioChem*, 2010, **11**, 954–957.
- 33 B. C. Roy and S. Mallik, *J. Org. Chem.*, 1999, **64**, 2969–2974.
- 34 K. M. K. Swamy, Y. J. Jang, M. S. Park, H. S. Koh, S. K. Lee, Y. J. Yoon and J. Yoon, *Tetrahedron Lett.*, 2005, **46**, 3453–3456.
- 35 P. Kuzmic, *Anal. Biochem.*, 1996, **237**, 260–273.